Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,093 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05909241RecruitingPhase 1
First study of BA1202 for advanced solid tumors
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
BeijingAges 18–70 - NCT06361043Recruiting
Adaptive radiation therapy for esophageal cancer
This study tests a new, more precise type of radiation therapy for esophageal cancer that adjusts the treatment in real time using a special CT scan. It aims to deliver a stronger dose to the tumor while sparing healthy tissue, which could improve outcomes.
BernAges 18 years+ - NCT05345587Recruiting
Digital monitoring plus proactive medication review during oral cancer treatment
This trial tests whether combining regular medication safety checks with electronic tracking of side effects can improve quality of life and help reduce economic burden for people taking cancer pills. It’s for people starting oral cancer therapy and using connected technology to report symptoms.
Brive-la-GaillardeAges 18 years+ - NCT06386835Recruiting
Comparing collagen paste to flap surgery for anal fistula
This trial tests a new collagen paste against standard flap surgery for a type of anal fistula. If you've already had a draining seton placed, you may be able to join this study to see which treatment works better.
Shatin, New TerritoriesAges 18 years+ - NCT06151743RecruitingPhase 2
Testing drug combo before throat cancer surgery
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05868174RecruitingPhase 1
Testing a targeted radiation drug plus a DNA repair blocker
This early-phase trial tests whether combining a targeted radiation medicine (177Lu-TLX250) with a DNA repair–blocking drug (peposertib) can shrink advanced solid tumors. It is designed for tumors that strongly show a marker called CAIX, which helps the radiation home in and may make treatment more effective.
North Ryde, New South WalesAges 18 years+ - NCT05649345RecruitingPhase 1
TR64 for advanced solid tumors that standard treatment failed
This early-phase trial studies TR64 in people with advanced solid cancers when standard treatments have stopped working or aren’t an option. It aims to see whether the drug can reduce tumors and is safe enough to keep studying.
Bengbu, AnhuiAges 18–75 - NCT06109558RecruitingPhase 1/Phase 2
LMV-12 plus Osimertinib for advanced lung cancer
This trial tests a new drug called LMV-12 combined with osimertinib for people with advanced non-small cell lung cancer that has certain genetic changes (MET amplification or RET fusion) and has stopped responding to standard EGFR inhibitor treatments.
Changsha, HunanAges 18 years+ - NCT07847281RecruitingPhase 1
New injectable drug for advanced solid tumors
This trial tests a new experimental drug (AK157D1) given by injection for people with advanced solid tumors that have not responded to standard care. The goal is to see if the drug can shrink tumors or slow their growth.
Harbin, HeilongjiangAges 18–75 - NCT05177055Recruiting
Sleep program for delayed sleep timing with mental health symptoms
This study offers a sleep-focused program to people whose sleep schedule is significantly shifted later than desired (delayed sleep phase disorder) along with moderate to severe mental health symptoms. It aims to see if treatment for the sleep problem can help in people already getting psychiatric care.
Bergen, TertnesAges 18–80 - NCT04050345Recruiting
Blood test to spot DNA changes after early colon cancer surgery
This study checks a “cell-free tumor DNA” blood test to see if cancer mutations can predict relapse after surgery for early colorectal cancer. If results look risky, they may help guide closer follow-up and future treatment decisions.
Milton Keynes, BuckinghamshireAges 18 years+ - NCT03198546RecruitingPhase 1
CAR T therapy for advanced liver cancer with GPC3
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07830407Recruiting
Personalized chemo response test for colorectal cancer
This study is testing a new lab test called ChemoINTEL that may help predict how well your colorectal cancer will respond to common chemotherapy drugs. The goal is to see if this test can help doctors choose the most effective treatment for you.
Liverpool, MerseysideAges 18 years+ - NCT06470256RecruitingPhase 1
Surgery plus targeted therapy and immunotherapy for advanced liver cancer
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
Wuhan, HubeiAges 18–75 - NCT03778814RecruitingPhase 1
Personalized T-cell therapy for advanced lung or solid tumors
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
Guanzhou, GuangdongAges 18–75 - NCT05779917RecruitingPhase 1
CAR-T cells for cancers that have specific target proteins
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
Guangzhou, GuangdongAges 18–75 - NCT03882840RecruitingPhase 1/Phase 2
T-like NK cell therapy for cancers with low MHC-I
This early-stage trial tests a lab-made immune cell treatment (T-like NK cells) for advanced cancers that have low or missing MHC-I on their cells. Because the treatment aims to “re-activate” the immune system against these cancers, you may be eligible if your cancer matches this feature and you meet safety requirements.
Guangzhou, GuangdongAges 18 years+ - NCT07824934RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, HEC-921, given alone or with other cancer treatments for people with advanced solid tumors. It may be an option for those who have tried standard treatments or who have a specific marker on their tumor.
ShanghaiAges 18 years+ - NCT07811037RecruitingPhase 1/Phase 2
Safety and effect of SGT003 for advanced solid tumors
This trial tests a new experimental medicine called SGT003 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the medicine is safe, how the body handles it, and whether it can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07810933RecruitingPhase 1/Phase 2
Study of a new ALK inhibitor for advanced cancer
This trial tests a new pill, SY-12321, for people with advanced cancer that has a specific change called ALK. The study aims to see if the drug can shrink tumors or slow their growth, and it may be an option if you've already tried other ALK-targeting treatments.
Guangzhou, GuangdongAges 18 years+ - NCT05979155RecruitingPhase 1
Study of NWY001 for advanced solid tumors
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
Guangzhou, GuangdongAges 18–75 - NCT07803848RecruitingPhase 2
Tarlatamab for extensive-stage small-cell lung cancer with poor performance status
This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.
BerlinAges 18 years+ - NCT06336707RecruitingPhase 1
HS-20089 combination for advanced solid tumors
This trial tests a new combination treatment called HS-20089 for people with advanced solid tumors. The goal is to see if it is safe and how well it works against cancer that has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06332170RecruitingPhase 1
HS-20093 combination safety study for advanced solid tumors
This study tests a new combination drug called HS-20093 for people with advanced solid tumors. It aims to see if it is safe and works against cancer that hasn't responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,093 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.